Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).

被引：12
|
作者：
Van der Heijden, Michiel Simon
Gupta, Shilpa
Galsky, Matt D.
Derleth, Christina Louise
Lee, Sue
Kataria, Ritesh S.
Powles, Thomas
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA
[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA
[4] Seagen Inc, Bothell, WA USA
[5] Astellas Pharma Inc, Northbrook, IL USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS589
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS589
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
    van der Heijden, M. S.
    Gupta, S.
    Galsky, M. D.
    Derleth, C.
    Steinberg, J.
    Kataria, R.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S605 - S606
  • [2] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Valderrama, B. Perez
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Gauna, D. E. Castellano
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    van der Heijden, B. M. S. Homet Moreno
    ANNALS OF ONCOLOGY, 2023, 34 : S1340 - S1340
  • [3] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Perez Valderrama, B.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano Gauna, D. E.
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1557 - S1558
  • [4] Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study
    Van Der Heijden, Michiel Simon
    Powles, Thomas
    Gupta, Shilpa
    Bedke, Jens
    Kikuchi, Eiji
    De Wit, Ronald
    Galsky, Matt D.
    Duran, Ignacio
    Necchi, Andrea
    Retz, Margitta
    Yu, Evan Y.
    Hoffman-Censits, Jean H.
    Iyer, Gopa
    Park, Se Hoon
    Su, Wen-Pin
    Parmar, Hema
    Guan, Xuesong
    Gorla, Seema Rao
    Homet Moreno, Blanca
    Valderrama, Begona Perez
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : LBA530 - LBA530
  • [5] EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
    Powles, Thomas
    van der Heijden, Michiel Simon
    Loriot, Yohann
    Bedke, Jens
    Valderrama, Begona P.
    Iyer, Gopa
    Kikuchi, Eiji
    Hoffman-Censits, Jeannie
    Vulsteke, Christof
    Drakaki, Alexandra
    Rausch, Steffen
    Arafat, Waddah
    Park, Se Hoon
    Swami, Umang
    Li, Jian-Ri
    Gorla, Seema Rao
    Homet Moreno, Blanca
    Yu, Xuesong
    Lu, Yi-Tsung
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [6] Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
    Matsubara, Nobuaki
    Yonese, Junji
    Kojima, Takahiro
    Azuma, Haruhito
    Matsumoto, Hiroaki
    Powles, Thomas
    Rosenberg, Jonathan E.
    Petrylak, Daniel P.
    Matsangou, Maria
    Wu, Chunzhang
    Campbell, Mary
    Yamashiro, Mayumi
    CANCER MEDICINE, 2023, 12 (03): : 2761 - 2771
  • [7] Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).
    Galsky, Matt D.
    Grande, Enrique
    Necchi, Andrea
    Koontz, Michael Zach
    Iyer, Gopa
    Campbell, Matthew T.
    Drakaki, Alexandra
    Loriot, Yohann
    Sokolowski, Kevin M.
    Zhang, Wei
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS717 - TPS717
  • [8] Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39
    Van Der Heijden, Michiel Simon
    Gupta, Shilpa
    Bedke, Jens
    Valderrama, Begona Perez
    Kikuchi, Eiji
    Iyer, Gopa
    Loriot, Yohann
    Dawson, Nancy Ann
    Hoffman-Censits, Jean H.
    Mar, Nataliya
    Sridhar, Srikala S.
    Maroto-Rey, Pablo
    Shin, Sang Joon
    Yu, Evan Y.
    Duran, Ignacio
    Birrenkott, Matthew
    Yu, Xuesong
    Shetty, Aditya
    Bavle, Abhishek Amar
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39
    Bedke, Jens
    Van Der Heijden, Michiel Simon
    Powles, Thomas
    Valderrama, Begona Perez
    Kikuchi, Eiji
    Iyer, Gopa
    Vulsteke, Christof
    Swami, Umang
    Castellano, Daniel
    Sarwar, Naveed
    Drakaki, Alexandra
    Hoffman-Censits, Jean H.
    Arafat, Waddah
    Andabekov, Timur
    Li, Jian-Ri
    Lu, Yi-Tsung
    Yu, Xuesong
    Shetty, Aditya
    Moreno, Blanca Homet
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)
    Petrylak, D. P.
    Rosenberg, J.
    Duran, I.
    Loriot, Y.
    Sonpavde, G.
    Wu, C.
    Gartner, E.
    Melhem-Bertrandt, A.
    Powles, T.
    ANNALS OF ONCOLOGY, 2018, 29
12345